First Immunotherapy Success in TKI-Resistant Lung Cancer Setting Demonstrates Power of AI-driven Immune Phenotyping by Lunit SCOPE IO - newly published in JCO
- Written by PR Newswire
![]() |
- Lunit SCOPE IO pivotal in first phase III trial successfully showing the efficacy of immunotherapy + chemotherapy for NSCLC patients with EGFR or ALK mutation - published in the Journal of Clinical Oncology and accepted by ESMO for oral presentation
SEOUL, South Korea, Oct. 24, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of...